Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC
Introduction: Gene fusion testing of ALK, ROS1, RET, NTRK, and MET exon 14 skipping mutations is guideline recommended in nonsquamous NSCLC (NS-NSCLC). Nevertheless, assessment is often hindered by the limited availability of tissue and prolonged next-generation sequencing (NGS) testing, which can p...
Similar Items
-
Predictive Impact of Diffuse Positivity for TTF-1 Expression in Patients Treated With Platinum-Doublet Chemotherapy Plus Immune Checkpoint Inhibitors for Advanced Nonsquamous NSCLC
by: Yuto Terashima, MD, et al.
Published: (2023-11-01) -
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
by: Daichi Fujimoto, MD, et al.
Published: (2022-02-01) -
Aging is Associated With Constipation in Japanese Patients With Ulcerative Colitis: A Post Hoc Analysis
by: Sen Yagi MD, PhD, et al.
Published: (2023-11-01) -
Long-term Prognosis and Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation: A Single-Center Experience
by: Yoshihide Ueda, MD, PhD, et al.
Published: (2017-12-01) -
Multicenter, Retrospective Study to Evaluate Necitumumab Plus Cisplatin and Gemcitabine After Immune Checkpoint Inhibitors in Advanced Squamous Cell Lung Cancer in Japan: The NINJA Study
by: Yasunori Murata, MD, PhD, et al.
Published: (2023-12-01)